🇺🇸 FDA
Pipeline program

Guselkumab, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab 1 mL PFS Placebo, Guselkumab 2 mL PFS Placebo

CNTO1959UCO3004

Phase 3 small_molecule active

Quick answer

Guselkumab, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab 1 mL PFS Placebo, Guselkumab 2 mL PFS Placebo for Moderate to Severly Active Ulcerative Colitis is a Phase 3 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Janssen-Cilag International N.V.
Indication
Moderate to Severly Active Ulcerative Colitis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials